Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 5
Submit an article Journal homepage
43
Views
4
CrossRef citations to date
0
Altmetric
Review

Nitric oxide-based molecular strategies for restenosis therapy

Chia-En LinNitroMed, Inc. 125 Spring Street, Lexington, MA 02421USATel: +1 781 266 4127; Fax: +1 781 274 8083;E-mail: [email protected]
,
David R JaneroNitroMed, Inc. 125 Spring Street, Lexington, MA 02421USATel: +1 781 266 4127; Fax: +1 781 274 8083;E-mail: [email protected]
&
David S GarveyNitroMed, Inc. 125 Spring Street, Lexington, MA 02421USATel: +1 781 266 4127; Fax: +1 781 274 8083;E-mail: [email protected]
Pages 483-495 | Published online: 10 May 2005

Bibliography

  • ROSS R, GLOMSET J: The pathogenesis of atherosclerosis. N Engl J. Med. (1976) 295:369–377.
  • ORFORD JL, SELWYN AP, GANZ P et al.: The comparative pathobiology of atherosclerosis and restenosis. Am. J. Cardiol (2000) 86:6H–11H.
  • ELLIS SG: Interventions in acute myocardial infarction. Circulation (1990) 81:1V43-1V50.
  • ARJOMAND H, TURI ZG, MCCORMICK D et al.: Percutaneous coronary intervention: historical perspectives, current status, and future directions. Am. Heart. J. (2003) 146:787–796.
  • • Authoritative consideration of the field of interventional cardiology and the problem that restenosis presents.
  • KHALIL AA: Catheter-based treatment of atherosclerosis, options for effective percutaneous intervention are plentiful. Postgrad. Med. (2004) 115:14–25.
  • MOSES JW, CARLIER S, MOUSSA I: Lesion preparation prior to stenting. Rev. Cardiovasc. Med. (2004) 5:S16–S21.
  • DETRE K, HOLUBKOV R, YEH Wet al: Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981: the NHLBI registry. N Engl J. Med. (1988) 318:265–270.
  • SCHWARTZ RS, HENRY TD: Pathophysiology of coronary artery restenosis. Rev. Cardiovasc. Med. (2002) 3:S4–S9.
  • RAJAGOPAL V ROCKSON SG: Coronary restenosis: a review of mechanisms and management. Am. J. Med. (2003) 115:547–553.
  • •• Clinical persepctives on the restenosisproblem in contemporary medicine.
  • BEYAR R: Novel approaches to reduce restenosis. Ann. NY Acad. Sci. (2004) 1015:367–378.
  • SCHIELE TM, KROTZ F, KLAUSS V: Vascular restenosis: striving for therapy. Expert Opin. Pharmacother. (2004) 5:2221–2232.
  • ROSANIO S, TOCCHI M, PATTERSON C et al: Prevention of restenosis after percutaneous interventions: the medical approach. Thromb. Haemost. (2000) 82:164–170.
  • LEVINE GN, KERN MJ, BERGER PB et al.: Management of patients undergoing percutaneous coronary revascularization. Ann. Int. Med. (2003) 139:123–136.
  • LAU KW, MAK KH, HUNG JS et al: Clinical impact of stent construction and design in percutaneous coroanry intervention. Am. Heart J. (2004) 147:764–773.
  • BARBATO E, MARCO J, WIJNS W: Direct stenting. Eur. Heart J. (2004) 24:304–403.
  • SIEGWART U, PUEL J, MIRKOVITCH V et al: Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Eng. J. Med. (1987) 316:701–706.
  • DUNDAR Y, HILL RA, BAKHAI A et al: Angioplasty and stents in coronary artery disease: a systematic review and meta-analysis. Scand. Cardiovasc. J. (2004) 38:200–210.
  • SCHWARTZ RS, CHRONOS NA, VIRMANI R: Preclinical restenosis models and drug-eluting stents. J. Am. Coll CardioL (2004) 44:1373–1385.
  • • Contemporary overview of the problems and pitfalls of translational restenosis research from leading clinician-scientists.
  • WELT FG, ROGERS C: Inflammation and restenosis in the stent era. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1769–1776.
  • INDOLFI C, MONGIARDO A, CURCIO A et al.: Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc. Med. (2003) 13:142–148.
  • FROESCHL M, OLSEN S, MAX et al: Current understanding of in-stent restenosis and the potential benefit of drug eluting stents. Curr. Drug Targets Cardiovasc. HaematoL Disord. (2004) 4:103–117.
  • SERRUYS PW, STRAUSS BH, BEATT KJ et al.: Angiographic follow-up after the placement of coronary-artery stents. N Engl J. Med. (1996) 334:1084–1089.
  • VETROVEC GW: Optimizing percutaneous coronary intervention outcomes. The next steps. Circulation (2005) 111:125–126.
  • SINDERMANN JR, VERIN V, HOPEWELL JW et al: Biological aspects of radiation and drug-eluting stents for the prevention of restenosis. Cardiovasc. Res. (2004) 63:22–30.
  • HARGAVA B, KARTHIKEYAN G, TRIPURANENI P: Intravascular brachytherapy: indications and management of adverse events. Am. J. Cardiovasc. Drugs 4:385–394.
  • KALUZA GL, RAINZER AE: Brachytherapy for restenosis after stenting for coronary artery disease: its role in the drug-eluting stent era. Curr. Opin. Cardiol 19:601–607.
  • LAU KW, JOHAN A, SIGWART U et ed.:A stent is not just a stent: stent construction and design do matter in its clinical performance. Singapore Med. J. (2004) 45:305–312.
  • ETTENSON DS, EDELMAN ER: Local drug delivery: an emerging approach in the treatment of restenosis. Vasc. Med. (2000) 5:97–102.
  • CHENG-LAI A, FRISHMAN WH: Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease. Am. J. Therapeut. (2004) 11:218–228.
  • SONODA S, HONDA Y, KATAOKA T et al.: Taxol-based eluting stents- from theory to human validation: clinical and intravascular ultrasound observations. Invas. Cardiol (2003) 15:109–114.
  • HILL RA, DUNDAR Y, BAKHAI A et ell.: Drug-eluting stents: an early systematic review to inform policy. Eur. Heart J. (2004) 25:902–919.
  • SCHOFER J, BODE C, SILBER S: Drug-eluting stents for in-stent restenosis and acute myocardial infarction. Herz (2004) 29:195–200.
  • WOODS TC, MARKS AR: Drug-eluting Stents. Ann. Rev. Med. (2004) 55:169–178.
  • •• State-of-the-art overview of drug-elutingstents and their present and anticipated roles in restenosis therapy.
  • VIRMANI R, KOLODGIE FD, FARB A et al: Drug eluting stents: are human and animal studies comparable? Heart (2003) 89:133–138.
  • BHATIA R, DHINDSA M: Drug-eluting Stents: new era and new concerns. Postgracl. Med. J. (2004) 80:13–18.
  • JANERO DR, EWING JF: Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential. Free Radic. BioL Med. (2000) 29:1199–1221.
  • •• Comprehensive, critical review of the (patho)physiological and therapeutic relationships between nitric oxide and restenosis that includes all laboratory and clinical efficacy trials up to 2000.
  • RUBIO AR, MORALES-SEGURA MA: Nitric oxide, an iceberg in cardiovascular physiology: far beyond vessel tone control. Arch. Med. Res. (2004) 35:1–11.
  • RAGHAVAN SAV, DIKSHIT M: Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine. PharmacoL Res. (2004) 49:397–414.
  • LANDMESSER U, HORNIG B, DREXLER H: Endothelial function. A critical determinant in atherosclerosis? Circulation (2004) 109:1127–1133.
  • HIGASHI Y, YOSHIZUMI M: New methods to evaluate endothelial function: method for assessing endothelial function in humans using a strain-gauge plethysmography: nitric-oxide dependent and -independent vasodilation. J. PharmacoL Sci. (2003) 93:399–404.
  • GOMMA AH, ELRAYESS MA, KNIGHT CJ et aL: The endothelial nitric oxide synthase (G1u298Asp and -786T C) gene polymorphisms are associated with coronary in-stent restenosis. Eur. Heart J. (2002) 23:1955–1962.
  • GORCHAKOVA 0, KOCH W, VON BECKERATH N et al.: Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. Eur. Heart J. (2003) 24:820–827.
  • PIATTI P, DI MARIO C, MONTI LD et aL: Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation (2003) 108:2074–2081.
  • WYKRETOWICZ A, DZIARMAGA M, SZCZEPANIK A et aL: Prospective evaluation of hydroperoxide plasma levels and stable nitric oxide end products in patients subjected to angiography for coronary artery disease. Int. J. CardioL (2003) 89:173–178.
  • KLPSHIDZE N, KEELAN MH, PETERSEN JR et aL: Photoactivation of vascular iNOS and elevation of cGMP in vivo: possible mechanism for photovasorelaxation and inhibition of restenosis in an atherosclerotic rabbit model. Photochem. PhotobioL (2000) 72:579–582.
  • BUERGLER JM, TIL FO, SCHULZ DGet aL: Use of nitric oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs. Coron. Artery Dis. (2000) 11:351–357.
  • AIZAWAY, KAWABE J, HASEBE Net aL: Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation (2001) 104:455–460.
  • MAFFIA P, IANARO A, SORRENTINO R et al.: Beneficial effects of no-releasing derivative of flurbiprofen (HCT-1026) in rat model of vascular injury and restenosis. Arterthsclero. Thromb. Vasc. Biol. (2002) 22:263–267.
  • KALINOWSKI M, ALFKE H, BERGEN S et aL: Comparative trial of local pharmacotherapy with L-arginine, r-hirudin, and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries. Radiology (2001) 219:716–723.
  • NAPOLI C, ALDINI G, WALLACE JL et aL: Efficacy and age-related effects of nitric oxide-releasing aspirin on exprimental restenosis. Proc. NatL Acad. Sci. USA (2002) 99:1689–1694.
  • BAEK SH, HRABIE JA, KEEFER LK et al.:Augmentation of intraperitoneal nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation (2002) 105:2779–2784.
  • INDOLFI C, TORELLA D, COPPOLA Cet aL: Physical training increases eNOS vascular expression and activity and reduces restenosis after balloon angioplasty or arterial stenting in rats. Circ. Res. (2002) 91:1190–1197.
  • ROLLAND PH, MEKKAOUIO C, PALASSI et aL: Efficacy of local molsidomine delivery from a hydrogel-coated angioplasty balloon catheter in the atherosclerotic porcine model. Cardiovasc. Intervent. RadioL (2002) 20:65–72.
  • ROLLAND PH, BARTOLI JM, PIQUET P et aL: Local delivery of NO-donor molsidomine post-PTCA improves haemodynamics, wall mechanics and histomorphometry in atherosclerotic porcine SFA. Eur. j Endovasc. Surg. (2002) 23:226–233.
  • WANG K, KESSLER PD, ZHOU Z et aL:Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. MoL Ther. (2003) 7:597–603.
  • HARNEK J, ZOUCAS E, SJUVE R et aL:Local infusion of the nitric oxide donor sin-1 after angioplasty. Effects on intimal hyperplasia in porcine coronary arteries. Acta Radiologica 44:395–402.
  • DO YS, KAO EY, GANAHA F et ell.: In-stent restenosis limitation with stent-based controlled-release nitric oxide: initial results in rabbits. Radiology 230:377–382.
  • UN GE, GARVEY DS, JANERO DR et aL: Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis. j Med. Chem. (2004) 47:2276–2282.
  • WOHRLE J, HOHER M, NUSSER T et al.: No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial. Can. J. CardioL 19:495–500.
  • JANERO DR: Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation. Free Radic. Biol. Med. (2000) 28:1495–1506.
  • BARBATO JE, TZENG E: Nitric oxide and arterial disease. J. Vasc. Surg. (2004) 40:187–193.
  • WANG PG, XIAN M, TANG X et aL: Nitric oxide donors: chemical activities and biological applications. Chem. Rev. (2002) 102(01091–1134. Excellent review on nitric oxide donors.
  • JANERO DR, BRYAN NS, SAIJO F et al.: Differential nitros(yfiation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc. Natl. Acad. Sci. USA (2004) 101:16958–16963.
  • GRUCHALA M, ROY H, BHARDWAJ S et al.: Gene therapy for cardiovascular diseases. Curr. Pharm. Des. (2004) 10:407–423.
  • KOPP CW, DE MARTIN R: Gene therapy for the prevention of restenosis. Curr. Vasc. PharmacoL (2004) 2:183–189.
  • SCHURMANN K, VORWERK D, BUCKER A et al.: Perigraft inflammation due to Dacron-covered stent-grafts in sheep iliac arteries: correlation of MR imaging and histopathologic findings. Radiology (1997) 204(3):757–763.
  • OTAL P, ROUSSEAU H, VINEL JP et aL: High occlusion rate in experimental transjugular intrahepatic portosystemic shunt created with a dacron-covered nitinol stent. J. Vasc. Interv. RadioL (1999) 10(2 Pt.1):183–188.
  • GOODWIN SC, YOON HC, CHEN G et al.: Intense inflammatory reaction to heparin polymer coated intravascular palmaz stents in porcine arteries compared to uncoated palmaz stents. Cardiovasc. Intervent. Radiol (2003) 26(2):158–167.
  • VIRMANI R, LIISTRO F, STANKOVIC G et al: Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. (2002) 106(21):2649–2651.
  • VAN DER HOEVEN BL, PIRES NM, WARDA HM et al.: Drug-eluting stents: results, proimises and problems. Int. J. Cardiol (2005) 99:9–17.

Websites

  • www.americanheart.org/statistics. AMERICAN HEART ASSOCIATION: Heart disease and stroke statistics - 2004 update. American Heart Association, Dallas, Texas (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.